Gynofem Healthcare and Pharmaceutical Unlisted Share Price Today
ISIN INE0NLL01017.
Gynofem Healthcare and Pharmaceuticals is a specialized pharmaceutical company in India , focused on the development and marketing of gynecological, fertility, and maternal healthcare products . The company offers a range of formulations catering to women’s health, including treatments for hormonal imbalance, infertility, pregnancy care, and postnatal support , with an emphasis on affordability and quality. Gynofem operates a formulation-driven business model , primarily engaged in developing…
Gynofem Healthcare and Pharmaceutical
Gynofem Healthcare and Pharmaceutical Unlisted Share Price Today
Gynofem Healthcare and Pharmaceuticals is a specialized pharmaceutical company in India, focused on the development and marketing of gynecological, fertility, and maternal healthcare products. The company offers a range of formulations catering to women’s health, including treatments for hormonal imbalance, infertility, pregnancy care, and postnatal support, with an emphasis on affordability and quality.
Gynofem operates a formulation-driven business model, primarily engaged in developing and distributing pharmaceutical products rather than large-scale in-house manufacturing. The company places strategic focus on niche therapeutic segments, product accessibility, and distribution reach, leveraging demand in women’s healthcare. Its performance is closely linked to product acceptance, doctor prescriptions, distribution expansion, and cost management, making operating efficiency critical to profitability.
Incorporated in 2022 and headquartered in Indore, Madhya Pradesh, Gynofem is an early-stage, fast-growing company with a developing market presence. The company operates through a network aimed at reaching both urban and semi-urban markets, positioning itself to benefit from the growing demand for specialized healthcare solutions in India.
EBITDA margin dropped from 0.97% to -22.62%, indicating sharp cost escalation and weak operating leverage.
Revenue growth rebounded to 13.05% in FY25, showing early traction despite losses.
PAT remains negative at -₹2.09 Cr with -42.33% margin, highlighting unstable profitability.
Income Statement
Market Share
P/E Ratio
Financial Ratio Comparison (FY25)
Key Managerial Personnel
As of FY26Mr. Nishikant R. Joshi is a Director, with over 30 years of experience in pharmaceutical management and sales. He has strong expertise in building pharma businesses, focusing on sales strategy, team leadership, and growth in specialized healthcare segments.
Mr. Anurag Mendhe is a Director, associated with the company since its incorporation and promoter group. He has been involved in the pharmaceutical business since 2016, contributing to the company’s growth and operations in the women’s healthcare segment.
